Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis.
Ghalib H, Modabber F.
Kinetoplastid Biol Dis. 2007 Aug 17;6:7.
Related citations
Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM.
Ann Trop Med Parasitol. 2005 Sep;99(6):563-9.
Leishmaniasis in Sudan. Visceral leishmaniasis.
Zijlstra EE, el-Hassan AM.
Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S27-58.
Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM; Leishmaniasis Research Group/Sudan.
Trans R Soc Trop Med Hyg. 2008 Jan;102(1):58-63. Epub 2007 Oct 25.
Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.
Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S59-76.
Post-kala-azar dermal leishmaniasis.
Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM.
Lancet Infect Dis. 2003 Feb;3(2):87-98. Review.
Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM.
Br J Dermatol. 2000 Jul;143(1):136-43.
Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
Saha S, Mazumdar T, Anam K, Ravindran R, Bairagi B, Saha B, Goswami R, Pramanik N, Guha SK, Kar S, Banerjee D, Ali N.
J Clin Microbiol. 2005 Mar;43(3):1269-77.
The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC).
Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG.
Clin Exp Immunol. 2000 Mar;119(3):523-9.
Recent advances in post-kala-azar dermal leishmaniasis.
Mondal D, Khan MG.
Curr Opin Infect Dis. 2011 Oct;24(5):418-22. Review.
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG.
Infect Immun. 2007 Sep;75(9):4648-54. Epub 2007 Jul 2.
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A.
Indian J Med Res. 2008 Jul;128(1):38-44.
Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S, Das NK, Barbhuiya JN, Chatterjee M.
Int J Dermatol. 2010 Aug;49(8):921-31. doi: 10.1111/j.1365-4632.2010.04558.x. Review.
Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).
Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J, Boelaert M, Rijal S.
PLoS Negl Trop Dis. 2011 Dec;5(12):e1433. Epub 2011 Dec 20.
Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE, el-Hassan AM, Ismael A.
Am J Trop Med Hyg. 1995 Apr;52(4):299-305.
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, Modabber F, Campos-Neto A, Reed SG.
Infect Immun. 2002 Aug;70(8):4215-25.
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.
Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, Goto Y, Guderian J, Howard RF, Reed SG.
Vaccine. 2010 Apr 26;28(19):3333-40. Epub 2010 Mar 4.
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N.
J Immunol. 2007 Oct 15;179(8):5592-603.
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.
Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG.
Vaccine. 2002 Sep 10;20(27-28):3292-303. Erratum in: Vaccine. 2002 Nov 1;20(31-32):3783..
High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis.
Gasim S, Theander TG, ElHassan AM.
Acta Trop. 2000 Feb 25;75(1):35-8.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on